Tony Coles’ New Company, Yumanity, To Focus On New Parkinson’s, Alzheimer’s, and ALS Treatments

December 15, 2014 7:07 PM

15 0

When Tony Coles sold Onyx Pharmaceuticals to Amgen for $10.4 billion last year, it was not the end of his time with the medical industry. He recently announced that he plans to start a new company that will focus on the use of yeast to develop a treatment for Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis (ALS, or Lou Gehrig’s disease).

The former chief executive of Onyx Pharmaceuticals recently declared, “I love a big problem and a good challenge and I think that this challenge is sized about right. We’ve got 50 million people around the world suffering from these diseases, $650 billion in economic costs, and lots of families like...

Read more

To category page